Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies

NCT06649708 is registered in ClinicalTrials.gov with Hanx Biopharmaceuticals (Wuhan) Co., Ltd. as lead sponsor.

NCT NCT06649708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies
Lead sponsor
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 30, 2024
Completion date
October 31, 2027
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor malignancies